Navigation Links
Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
Date:7/29/2010

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) announced that results from its COR-I trial of Contrave® were published online today in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration. Results show that patients taking Contrave were two to three times more likely to lose at least 5% or 10% of their body weight compared to those taking placebo, on both an intent-to-treat (ITT) and completers basis.

Many patients with obesity are at higher risk for diabetes and cardiovascular disease, so evaluating the impact of weight loss on markers of cardiovascular and metabolic risk was a key objective of the COR (Contrave Obesity Research) Phase 3 program. Results from COR-I showed that treatment with Contrave resulted in significant improvements over placebo in waist circumference, insulin resistance, HDL cholesterol, triglycerides, and hsCRP, which are well-known and accepted measures of cardiometabolic risk. Patients taking Contrave also showed significant improvements in patient-reported control of eating, including reduced food cravings and reduced difficulty resisting food cravings.

"The secondary health benefits of weight loss are critical to understanding the potential role of pharmacotherapy in managing overweight and obese patients," said Frank Greenway, M.D., Medical Director at the Pennington Center Outpatient Research Clinic and lead investigator for the study. "This study showed that treatment with Contrave has meaningful impact on markers of cardiometabolic risk, demonstrating its pote
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 Many new dentists who are ... to ensure that their practice will be a success. DentalDisposables.net ... supplies they use the most can make all the difference. ... have recently discovered that purchasing discount dental supplies ... According to successful dentists across the United ...
(Date:7/24/2014)... July 24, 2014 Talyst, a market leader ... National Association of State Veterans Homes (NASVH) Summer Conference ... goal of the NASVH is to ensure that each ... long term health care and respect which they have ... With the InSite® Remote Dispensing System, Talyst can help ...
(Date:7/24/2014)... BURLINGTON, Mass. , July 24, 2014 ... asthma, pulmonologists in the EU5 countries ( France ... Italy , Spain and ... generally positive view of the first once-daily long-acting beta2 ... pulmonologists expect robust uptake of Relvar as a first-line ...
Breaking Medicine Technology:Dental Supplies Online is Key to Dental Success...Really! 2Talyst Exhibits at the National Association of State Veterans Homes Summer Conference 2Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 2Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 3
... Oct. 11 More than 170 industry experts and ... four executive workshops at AdvaMed 2010: The MedTech ... its fourth year, this annual medical technology industry developed ... U.S. and around the world.   "This ...
... Holdings Corp. (Nasdaq: TLCR ) will issue its ... October 28, 2010. Due to the pending merger with Grifols, ... discuss its third quarter results. About Talecris ... Talecris Biotherapeutics is a global biotherapeutic and biotechnology company ...
Cached Medicine Technology:Medical Technology, Funding & Government Experts Address Business, Investment, Reimbursement, Compliance, Innovation, Regulatory and Legal Issues at AdvaMed 2010 2Medical Technology, Funding & Government Experts Address Business, Investment, Reimbursement, Compliance, Innovation, Regulatory and Legal Issues at AdvaMed 2010 3
(Date:7/24/2014)... shuts off nighttime production of the hormone melatonin, renders ... breast cancer drug, says a new study by Tulane ... and Melatonin Disruption by Exposure to Light at Night ... published in the journal Cancer Research , is ... the success of tamoxifen in treating breast cancer. , ...
(Date:7/24/2014)... Ticket Down is a reliable source ... at the Sports Authority Field on July 26th. For the ... has brought some of the best club teams from around the ... still being raved about weeks after its completion, fans – new ... of the biggest stars in the world compete. Some of these ...
(Date:7/24/2014)... 2014 Four Seasons Resort Maui ... its $3 million renovation of the famed Maile suite ... suites, just in time to welcome summer guests vacationing ... direction from the internationally-acclaimed BraytonHughes Design Studios, San Francisco ... property and the largest in Hawaii—received a complete re-envisioning. ...
(Date:7/24/2014)... In a July 9th article in the Money ... Lotus Blossom Consulting LLC , was quoted in a Family ... Cut the High Cost of Infertility . Her advice began ... maximize your chance of success from the first attempt.” The ... “I am always happy to talk with the media ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 CarePoint ... specialist in hematology and oncology, Dr. Hitendra Upadhyaya, ... Our system welcomes Dr. Upadhyaya to the community. ... CarePoint Health Medical Group, a comprehensive network of ... a wide range of specialties. This latest acquisition ...
Breaking Medicine News(10 mins):Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 2Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 4Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 5Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 2Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 3Health News:Dr. Upadhyaya Joins CarePoint Health Medical Group 2
... on Science, Not IdeologyWASHINGTON, March 23 Today, the ... York ruled that the Food and Drug Administration (FDA) ... dedicated emergency contraceptive product) based on age was "arbitrary ... faith decision-making." The court ordered the FDA to extend ...
... Recommended levels in foods need to be increased, experts ... the course of two decades, vitamin D levels have ... Low levels of vitamin D have been associated with ... adults. Recent research has also linked insufficient vitamin D ...
... seen with tightest control of risk factors, researchers report ... control of the major risk factors for heart disease ... a new study shows. , And so the current ... LDL cholesterol might need to be tightened even further, ...
... a Decision Based on Scientific Fact, Not PoliticsNEW YORK, March ... the Eastern District of New York rejected the Food and ... emergency contraceptive Plan B to women over 18, ruling that ... The court ordered the agency to reconsider its decision. ...
... in Virginia, West Virginia and Maryland to hold annual convention recognizing ... ... 23, 2009 -- 200 emergency and 911 professionals will gather in ... safety sector. The 16th Annual Tri-State Telecommunicators Banquet and Awards ...
... Inform Healthcare DecisionsPHILADELPHIA, March 23 ... when selecting a hospital for treatment, thanks to ... and facility.Synthesizing extensive data from the 2003-2007 ... Hospital Performance Reports (PHC4) into a searchable format, ...
Cached Medicine News:Health News:Advocates for Youth Applauds Court Ruling on EC Age Restriction 2Health News:Many Americans Fall Short on Their Vitamin D 2Health News:Many Americans Fall Short on Their Vitamin D 3Health News:Many Americans Fall Short on Their Vitamin D 4Health News:Lowest Blood Pressure, Cholesterol Levels the Best 2Health News:Lowest Blood Pressure, Cholesterol Levels the Best 3Health News:Federal Court Rules FDA Must Reconsider Plan B Decision 2Health News:Federal Court Rules FDA Must Reconsider Plan B Decision 3Health News:LLE to Sponsor 16th Annual Tri-State Telecommunicators Banquet and Awards Ceremony 2Health News:New Site Compares Pennsylvania Hospitals 2
... mini-cells has always distinguished itself by ... tradition continues with the patented XCell ... gel tension wedge in place of ... models makes the XCell SureLock and ...
... Multidizer is designed with a variety of ... - all in one unit. Shake, rock, ... operating compartments allow for hybridization and blotting ... , The upper chamber uses a ...
... unit ideal for use in laboratories with low ... set at 12 rpm , Temperature control ... capacity of four 35 x 150mm bottles, eight ... , Consistent, repeatable results achieved with microprocessor ...
Maxi XL Hybridization Oven for Extra Large bottles. 6 bottle (70 mm) rotisserie + shaker tray available for simultaneous use. Includes linear and orbital shaker trays, 4 extra large bottles, pack o...
Medicine Products: